Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
Authors:
- Momoko HayashiMHMomoko Hayashi
- Yoshibumi KuwabaraYKYoshibumi Kuwabara
- Kuniji ItoKIKuniji Ito
- Yoshiaki HojoYHYoshiaki Hojo
- Fumiaki AraiFAFumiaki Arai
- Kazuki KamijimaKKKazuki Kamijima
- Masakazu TakeiriMTMasakazu Takeiri
- Xiaojing WangXWXiaojing Wang
- Pan DiaoPDPan Diao
- Jun NakayamaJNJun Nakayama
- Naoki TanakaNaoki Tanaka
Open Access
- 27 January 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 384
Abstract
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease which may progress into liver fibrosis and cancer. Since NASH patients have a high prevalence of atherosclerosis and ensuing cardiovascular diseases, simultaneous management of NASH and atherosclerosis is required. Currently, rodents are the most common animal models for NASH and accompanying liver fibrosis, but there are great differences in lipoprotein profiles between rodents and humans, which makes it difficult to reproduce the pathology of NASH patients with atherosclerosis. Rabbits can be a promising candidate for assessing NASH and atherosclerosis because lipoprotein metabolism is more similar to humans compared with rodents. To develop the NASH model using rabbits, we treated the Japanese White rabbit with a newly developed high-fat high-cholesterol diet (HFHCD) containing palm oil 7.5%, cholesterol 0.5%, and ferrous citrate 0.5% for 16 weeks. HFHCD-fed rabbits exhibited NASH at 8 weeks after commencing the treatment and developed advanced fibrosis by the 14th week of treatment. In addition to hypercholesterolemia, atherosclerotic lesion developed in the aorta after 8 weeks. Therefore, this rabbit NASH model might contribute to exploring the concurrent treatment options for human NASH and atherosclerosis.Keywords
Funding Information
- Kitayama Labes Co., Ltd.
This publication has 56 references indexed in Scilit:
- Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependentJournal of Hepatology, 2014
- Cholesterol-Induced Non-Alcoholic Fatty Liver Disease and Atherosclerosis Aggravated by Systemic InflammationPLOS ONE, 2014
- Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver DiseaseCell Metabolism, 2012
- Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitisHepatology, 2012
- Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisWorld Journal of Gastroenterology, 2012
- Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expressionBiochemical and Biophysical Research Communications, 2011
- Down-regulation of SREBP-1c is associated with the development of burned-out NASHJournal of Hepatology, 2010
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2010
- M1721 Clinical Features of Nonalcoholic Fatty Liver Disease Developed After PancreaticoduodenectomyGastroenterology, 2009
- Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liverAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005